Core Insights - Coherus Oncology is transitioning into an innovative oncology company focused on overcoming immune resistance in cancer, with a strong emphasis on its commercial PD-1 therapy LOQTORZI and new pipeline assets acquired from Surface Oncology [5][22]. Group 1: LOQTORZI Overview - LOQTORZI is described as a next-generation PD-1 therapy with high-affinity binding, effective in low PD-L1 cancers, and is currently labeled for low PD-L1 esophageal cancer in the EU [1]. - Sales of LOQTORZI increased significantly from $19.1 million in 2024 to $40.8 million in 2025, with expectations of reaching $15–16 million per quarter in 2026 and targeting a 70% market share by 2028, equating to approximately $175 million annualized [7][10]. - The company is pursuing a $33 billion opportunity based on ongoing trials in the U.S. [2]. Group 2: Financial Developments - Coherus completed the sale of UDENYCA to Intas for an upfront payment of $483 million, with additional payments expected, which will support the company's financial stability [3]. - The company has paid down nearly $480 million in debt and retained $250 million on its balance sheet to fund development efforts [4][7]. Group 3: Pipeline Progress - The pipeline includes tagmokitug, a CCR8 Treg depleter, and casdozokitug, an IL-27 blocker, with promising clinical outcomes reported, including a 38% overall response rate in first-line hepatocellular carcinoma [6][17]. - Tagmokitug is being studied in various cancers, including head and neck and gastrointestinal cancers, and is expected to enter prostate cancer studies in collaboration with Johnson & Johnson [12][15]. - Coherus is also exploring additional collaborations for tagmokitug and casdozokitug, aiming for ex-U.S. licensing to manage development costs [21].

Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% growth year-over-year compared to $19.1 million in 2024 [28] - For Q4 2025, net revenue was $12.4 million, reflecting an 11% growth over Q3 2025, with a strong quarter-over-quarter demand growth of 15.5% in Q4 [28] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025, significantly lowering interest costs [34][38] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology commercial product, more than doubled its sales in 2025 compared to 2024, with expectations of continued growth driven by new patient starts and increased market penetration [6][28] - The company anticipates achieving peak market share for LOQTORZI by 2028, targeting $175 million in annualized revenues, which would represent about 70% market share of the $250 million total addressable market [7][32] Market Data and Key Metrics Changes - The NCCN guidelines for nasopharyngeal carcinoma (NPC) were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which has stimulated growth in 2025 [29] - The company is focusing on expanding its reach in the community segment, where off-label immuno-oncology (IO) treatments persist [29] Company Strategy and Development Direction - Coherus has transitioned from a biosimilar company to an innovative oncology company, focusing on overcoming immune resistance in cancer through strategic acquisitions and product development [4][6] - The company is investing in its pipeline, particularly in tagmokitug and Casdozokitug, with multiple clinical readouts expected in 2026 [10][27] - The strategic partnership with Johnson & Johnson for tagmokitug is seen as a validation of the company's scientific competency and a pathway to further collaborations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits compared to chemotherapy alone [30] - The company is well-positioned financially, with sufficient funding to support operations and pipeline advancements through 2026 and into 2027 [9][39] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [30] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, reflecting a 35% reduction [34] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales performance, which could provide additional financial support [36] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - Approximately 25% of the business came from new patients in 2025, with expectations that this mix will shift slightly more towards new patients in 2026 as the duration of therapy for existing patients increases [46] Question: What are the promotional sensitivities of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [49] Question: Can you discuss the additional investments in commercial infrastructure? - The company has expanded its field force by 15% and added inside sales representatives to target tier 2 accounts, along with investments in IT infrastructure to capture patient opportunities [51][52] Question: What are the plans for exploring a triple combination with TAGMO? - The initial step will be to evaluate the combination of tagmokitug and pasritamig before considering additional combinations [57] Question: How will data from ongoing trials be disclosed? - Data will be reported as it becomes available, either aligned with congress submission deadlines or through corporate disclosures [62]

Financial Data and Key Metrics Changes - Coherus Oncology reported a net revenue of $40.8 million for the full year 2025, representing a 113% increase from $19.1 million in 2024 [35] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025 [4][41] - SG&A expenses decreased to $23.6 million in Q4 2025 from $29.6 million in Q4 2024, marking the fourth consecutive quarter of flat or declining expenses [44] - R&D expenses increased to $31 million in Q4 2025 compared to $20.8 million in Q4 2024, reflecting ongoing investments in the pipeline [44] Business Line Data and Key Metrics Changes - LOQTORZI, the company's first innovative oncology product, saw its sales more than double in 2025 compared to 2024 [6][49] - For Q4 2025, LOQTORZI net revenue was $12.4 million, an 11% growth over Q3 2025, driven by a 15.5% increase in demand [35] - The company anticipates achieving peak market share of approximately 70% in the nasopharyngeal carcinoma (NPC) market by 2028, equating to $175 million in annualized revenues [7][40] Market Data and Key Metrics Changes - The NCCN guidelines for NPC were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which stimulated growth in 2025 [36] - The addressable market for LOQTORZI is estimated at $250 million, with significant opportunities remaining, particularly in the community segment [35][36] Company Strategy and Development Direction - Coherus has transitioned to focus on innovative oncology, particularly in overcoming immune resistance in cancer, following the acquisition of Surface Oncology [4] - The company aims to leverage LOQTORZI as a revenue generator while advancing its pipeline, including tagmokitug and Casdozokitug, which are positioned for broad clinical utility [6][10] - Strategic partnerships, such as the collaboration with Johnson & Johnson, are seen as key to expanding market reach and enhancing the value of the pipeline [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth trajectory, supported by strong clinical data showing significant survival benefits over chemotherapy alone [37] - The company is well-funded through 2026 and into 2027, allowing for continued investment in its promising pipeline and commercial efforts [9][41] - Management highlighted the importance of educating oncologists on the new survival data to drive adoption of LOQTORZI [38][39] Other Important Information - The company has reduced its headcount from approximately 228 at the end of 2024 to about 147 at the end of 2025, a reduction of about 35% [41] - Coherus is eligible for two earn-out sales milestones of $37.5 million each based on UDENYCA sales, which could provide additional financial support [43] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - In 2025, approximately 25% of business came from new patients, with the expectation that this mix will shift slightly more towards new patients in the future [51][53] Question: What is the promotional sensitivity of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [57] Question: What are the plans for exploring a triple combination with Tagmo? - The initial step will be to evaluate the combination of Tagmo and pasritamig before considering additional combinations [64] Question: How will data from ongoing trials be disclosed? - Data will be reported as it matures, either at congresses or through corporate disclosures, depending on the timing of patient accrual and scans [70] Question: What are the important updates on the competitive front for CCR8 this year? - The company anticipates more data disclosures from competitors, which could impact development strategies [80]

Financial Data and Key Metrics Changes - Coherus Oncology reported LOQTORZI net revenue of $40.8 million for the full year 2025, a 113% increase from $19.1 million in 2024 [27] - The company reduced its secured and convertible debt by over 90% from $480 million to $38.8 million by the end of 2025 [3][32] - SG&A expenses decreased to $23.6 million in Q4 2025 from $29.6 million in Q4 2024, marking the fourth consecutive quarter of flat or declining expenses [36] Business Line Data and Key Metrics Changes - LOQTORZI sales more than doubled in 2025 compared to 2024, with Q4 net revenue reaching $12.4 million, an 11% growth over Q3 [27][31] - The company launched LOQTORZI in 2024, targeting a $250 million addressable market for recurrent, locally advanced, or metastatic Nasopharyngeal Carcinoma [4] Market Data and Key Metrics Changes - The NCCN guidelines for NPC were updated in late 2024, positioning LOQTORZI as the only preferred treatment for recurrent and metastatic NPC, which stimulated growth in 2025 [28] - The company anticipates achieving peak market share of approximately 70% in the NPC market by 2028, equating to $175 million in annualized revenues [6][31] Company Strategy and Development Direction - Coherus has transitioned to focus on innovative oncology, particularly in overcoming immune resistance in cancer, following the acquisition of Surface Oncology [3] - The company aims to leverage LOQTORZI as a revenue generator while advancing its pipeline products, including tagmokitug and Casdozokitug, which are positioned for broad clinical utility [5][9] - Strategic partnerships, such as the collaboration with Johnson & Johnson, are seen as key to unlocking value and expanding market opportunities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in LOQTORZI's growth due to its unique position in the market and the compelling survival data presented at ESMO Asia [29] - The company is focused on educating oncologists about the benefits of LOQTORZI, particularly in light of new survival data that shows significant advantages over chemotherapy alone [30] - Management believes that the financial strategy, including reduced debt and growing revenues, positions the company well for future growth [40] Other Important Information - The company has made significant investments in commercial infrastructure to support LOQTORZI's growth, including expanding its sales force and enhancing data analytics capabilities [30] - Coherus is on track for initial data readouts from its clinical programs in mid-2026, which will inform future development strategies [18][26] Q&A Session Summary Question: Can you provide more color on the dynamic between new patient starts and repeat patients in 2025? - Approximately 25% of the business came from new patients in 2025, with expectations that this mix will shift slightly more towards new patients in the future [45] Question: What is the promotional sensitivity of LOQTORZI? - LOQTORZI is highly promotion sensitive, requiring continuous reminders to physicians about its benefits due to the rarity of NPC cases [48] Question: Can you discuss the additional investments in commercial infrastructure? - The company has expanded its field force by 15% and added inside sales representatives to target tier 2 accounts, along with investments in IT infrastructure to capture patient opportunities [49][50] Question: What are the plans for exploring a triple combination with TAGMO? - The initial step will be to evaluate the combination of tagmokitug and pasritamig before considering additional combinations [55] Question: How will data from ongoing trials be disclosed? - Data will be reported as it matures, either at congresses or through corporate disclosures, depending on the timing of patient accrual and scans [61] Question: What is the maturation timeline for the Casdozokitug frontline HCC study? - The maturation timeline is expected to be between 6 to 12 months, with ongoing data collection to inform future reports [68]

Core Insights - Coherus Oncology reported significant growth in LOQTORZI net revenue, which more than doubled to $40.8 million in 2025 from $19.1 million in 2024, indicating strong market demand and successful sales strategies [1][2] - The company successfully reduced its secured and convertible debt by 90%, decreasing from $480 million to $38.8 million over the period of 2024-2025, enhancing its financial stability [1][2] - As of December 31, 2025, Coherus had $172.1 million in cash, cash equivalents, and marketable securities, reflecting a solid liquidity position [1][17] Financial Performance - For Q4 2025, net revenue from continuing operations was $12.7 million, up from $7.7 million in Q4 2024, driven by increased demand for LOQTORZI [5][9] - The cost of goods sold (COGS) for Q4 2025 was $4.0 million, compared to $2.8 million in Q4 2024, primarily due to volume growth of LOQTORZI [10] - Research and development (R&D) expenses rose to $31.0 million in Q4 2025 from $20.8 million in Q4 2024, reflecting increased investment in pipeline candidates [11] Pipeline Development - Coherus is advancing its innovative oncology pipeline, including casdozokitug, which is in a Phase 2 study for hepatocellular carcinoma, and tagmokitug, a highly selective CCR8 targeting antibody [2][21] - Tagmokitug has shown promising results in preclinical studies, demonstrating high selectivity and significant efficacy in depleting CCR8+ tumor regulatory T cells [4][6] - The company plans to initiate combination studies with tagmokitug and LOQTORZI, as well as with Johnson & Johnson's T-cell engager pasritamig in metastatic castration-resistant prostate cancer [2][13] Market Position - LOQTORZI remains the only FDA-approved treatment in the U.S. for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma, representing a $250 million addressable market [5] - The company is strategically positioned with growing revenues from LOQTORZI and potential deal opportunities across its portfolio, indicating a robust market presence [2][20]

Core Insights - Coherus is launching LOQTORZI for nasopharyngeal carcinoma (NPC), addressing an unmet medical need with an estimated 2,000 patients annually who previously relied on chemotherapy or off-label immuno-oncology treatments [1] - The company has undergone a significant transformation, enhancing its team, board, and investor base, and has recently completed a financing round, resulting in a strong balance sheet with cash reserves [2] - Coherus has reduced its debt by approximately 90%, from about $480 million to $3.7 million, and added $250 million to its balance sheet, which supports its oncology pipeline development [3][7] Commercial Launch and Financial Performance - LOQTORZI's commercialization is accelerating, generating about $19 million in sales in 2024, with sales doubling in 2025, and the company expects to reach a self-funding status at approximately $15-16 million per quarter by 2026 [6][8] - Management targets a run rate of roughly $175 million per year by 2028, representing about 70% penetration of a $250 million market opportunity [17] - LOQTORZI has shown a significant overall survival benefit of 65 months compared to 34 months with chemotherapy alone, and it is listed as the only "preferred" option in the NCCN guidelines for NPC [9] Pipeline Developments - Coherus is advancing its pipeline with tagmokitug (anti-CCR8) showing selective tumor Treg depletion of 52-97% without dose-limiting toxicities, and casdozokitug (anti-IL-27) demonstrating liver/lung-specific activity [5][16] - A randomized phase II readout for casdozokitug is expected in mid-2026, with ongoing studies showing improved response rates in liver cancer when combined with standard therapies [19][20] - The company is pursuing partnerships to share costs in pivotal trials for its pipeline assets, including collaborations with Johnson & Johnson [14][15] Strategic Focus - Coherus is focused on three main priorities: enhancing the commercial launch of LOQTORZI, advancing its pipeline assets, and implementing a financial strategy to reduce development costs while maximizing shareholder value [21]

Coherus Oncology FY Conference Summary Company Overview - **Company**: Coherus Oncology (NasdaqGM:CHRS) - **Date of Conference**: March 04, 2026 - **Focus**: Transformation into an innovative oncology company, with significant debt reduction and product development initiatives Key Metrics and Financials - **Debt Reduction**: Reduced indebtedness by 90%, from approximately $480 million to $3.7 million in senior secured debt [2][6] - **Cash Position**: Strong balance sheet with $172 million at the end of Q4, further improved with recent financing [9] - **Sales Growth**: Sales of LOQTORZI increased from $19 million in 2024 to approximately $38 million in 2025, with expectations for continued growth in 2026 [5][10] Product Development and Pipeline LOQTORZI - **Indication**: Nasopharyngeal carcinoma (NPC) with a significant unmet need; launched in 2024 [7] - **Market Opportunity**: Estimated market size of $250 million, with a target of achieving $175 million in annual sales by 2028 [11] - **Sales Strategy**: Enhanced commercial team and sophisticated data acquisition tools to identify and reach patients [8][9] - **Clinical Data**: Demonstrated overall survival benefit of 65 months with LOQTORZI compared to 34 months with chemotherapy alone [4] Tagmokitug (Anti-CCR8 Antibody) - **Mechanism**: Targets T-regulatory cells (Tregs) selectively, showing 52%-97% depletion in tumors without affecting CD4s and CD8s [15][16] - **Tumor Types**: High potential across various solid tumors including head and neck, gastrointestinal, and breast cancers [17] - **Clinical Development**: Ongoing studies to optimize dosing and understand the best contexts for treatment [18][19] - **Partnerships**: Interest from larger companies for collaborations, particularly in combination therapies [23][24] Casdozokitug (Anti-IL-27) - **Mechanism**: Inhibits IL-27 to activate T cells and NK cells, showing promising results in liver and lung cancers [36][39] - **Clinical Data**: Achieved a 17% complete response rate in liver cancer, significantly higher than the previous highest of 8% [41] - **Ongoing Studies**: Randomized phase 2 study with initial readout expected mid-year 2026 [43] Strategic Insights - **Transformation Strategy**: Focus on product, clinical, and financial strategies to enhance investor value [52] - **Market Positioning**: Coherus aims to leverage its unique product offerings and partnerships to address significant gaps in oncology treatment [24][25] - **Future Outlook**: Anticipation of strong data readouts and continued growth in sales and clinical advancements [53] Additional Considerations - **Collaborative Opportunities**: Open to various licensing and partnership arrangements to reduce clinical trial costs and enhance development capabilities [25] - **Biomarker Strategy**: Potential to develop a biomarker strategy based on CCRA presence in tumors to enrich patient populations [32] This summary encapsulates the key points discussed during the Coherus Oncology FY Conference, highlighting the company's strategic direction, product pipeline, and financial health.

Core Viewpoint - Coherus Oncology has introduced its investigational anti-CCR8 monoclonal antibody, tagmokitug, which shows high selectivity and efficacy in targeting CCR8+ T regulatory cells in solid tumors, indicating its potential as an anticancer treatment [1][3][4]. Group 1: Scientific Evidence and Mechanism - The publication in Molecular Cancer Therapeutics highlights tagmokitug's picomolar binding affinity and its ability to selectively eliminate CCR8+ T regulatory cells without off-target binding [1][3]. - Preclinical and clinical studies demonstrate that tagmokitug induces significant tumor regression in mouse models, especially when combined with anti-PD-1 antibody treatment [4]. - The first-in-human clinical study confirms that tagmokitug leads to selective reductions in CCR8+ Tregs in cancer patients, establishing proof of mechanism [5]. Group 2: Clinical Development and Pipeline - Tagmokitug is currently undergoing Phase 1b/2a clinical trials in combination with the PD-1 inhibitor toripalimab and chemotherapy for patients with various solid tumors [6][8]. - Coherus Oncology's pipeline includes multiple antibody immunotherapy candidates aimed at enhancing immune responses to improve cancer treatment outcomes [8]. Group 3: Company Overview - Coherus Oncology is a commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI®, and a promising pipeline targeting various cancers [7]. - The company's strategy focuses on growing sales of LOQTORZI in nasopharyngeal carcinoma and advancing new indications in combination with its pipeline candidates [7].